Luteolin, a polyphenolic flavone, has been demonstrated to exert anti-tumor activity in various cancer types.\nCisplatin drug resistance is a major obstacle in the management of ovarian cancer. In the present study, we\ninvestigated the chemo-sensitizing effect of luteolin in both cisplatin-resistant ovarian cancer cell line and a mice\nxenotransplant model. In vitro, CCK-8 assay showed that luteolin inhibited cell proliferation in a dose-dependent\nmanner, and luteolin enhanced anti-proliferation effect of cisplatin on cisplatin-resistant ovarian cancer CAOV3/DDP\ncells. Flow cytometry revealed that luteolin enhanced cell apoptosis in combination with cisplatin. Western blotting\nand qRT-PCR assay revealed that luteolin increased cisplatin-induced downregulation of Bcl-2 expression. In\naddition, wound-healing assay and Matrigel invasion assay showed that luteolin and cisplatin synergistically\ninhibited migration and invasion of CAOV3/DDP cells. Moreover, in vivo, luteolin enhanced cisplatin-induced\nreduction of tumor growth as well as induction of apoptosis. We suggest that luteolin in combination with cisplatin\ncould potentially be used as a new regimen for the treatment of ovarian cancer.
Loading....